These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 3167234)

  • 41. CA 72-4 radioimmunoassay in the diagnosis of malignant effusions. Comparison of various tumor markers.
    Ferroni P; Szpak C; Greiner JW; Simpson JF; Guadagni F; Johnston WW; Colcher D
    Int J Cancer; 1990 Sep; 46(3):445-51. PubMed ID: 2394511
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Tumor markers in the upper intestinal tract--stomach and pancreas].
    Pointner R; Conrad F; Schwab G
    Wien Klin Wochenschr; 1989 Jul; 101(14):482-4. PubMed ID: 2773485
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CA72-4 compared with carcinoembryonic antigen as a tumour marker for gastric cancer.
    Hamazoe R; Maeta M; Matsui T; Shibata S; Shiota S; Kaibara N
    Eur J Cancer; 1992; 28A(8-9):1351-4. PubMed ID: 1515249
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CA 15.3 and CEA plasma level monitoring in patients with breast cancer.
    Martoni A; Ercolino L; Bellanova B; Zanichelli L; Canova N; Pannuti F
    Int J Biol Markers; 1988; 3(3):154-8. PubMed ID: 3230334
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nipple fluid carcinoembryonic antigen and prostate-specific antigen in cancer-bearing and tumor-free breasts.
    Zhao Y; Verselis SJ; Klar N; Sadowsky NL; Kaelin CM; Smith B; Foretova L; Li FP
    J Clin Oncol; 2001 Mar; 19(5):1462-7. PubMed ID: 11230492
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Clinical evaluation of a new tumor marker, CA 15-3, in breast cancer; a comparative study with CEA].
    Komuro K; Watanabe K; Ishida T; Sakurai M; Amano R; Hagiwara H; Hara Y; Hanzawa T; Itsubo K
    Gan To Kagaku Ryoho; 1986 Oct; 13(11):3145-9. PubMed ID: 3465273
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pretreatment concentrations of breast carcinoma antigen (CA 15.3) and mucin-like carcinoma-associated antigen in patients with carcinoma of the breast.
    Góźdź SS; Kowalska MM; Słuszniak JT; Słuszniak A; Korejba W; Bukowski J; Banasińska E; al-Jazzaf H; Szymendera JJ
    Tumour Biol; 1989; 10(2):103-8. PubMed ID: 2734547
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Occurrence of carcinoma-associated antigen 494 in colorectal cancer tissue and in Patients' sera during metastatic disease.
    Lindhorst E
    Tumour Biol; 2000; 21(2):116-22. PubMed ID: 10686541
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of CA M26, CA M29, CA 15-3 and CEA as circulating tumor markers in breast cancer patients.
    Dnistrian AM; Schwartz MK; Greenberg EJ; Smith CA; Schwartz DC
    Tumour Biol; 1991; 12(2):82-90. PubMed ID: 2028182
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Study on the clinical usefulness of NCC-ST-439 in breast cancer].
    Takahashi H; Nakanishi K; Taguchi K; Hasumi T; Hamada H; Sasaki F; Hata Y; Uchino J
    Gan To Kagaku Ryoho; 1991 Feb; 18(2):245-9. PubMed ID: 1992918
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A comparison of CA-549 with CA 15-3 and MCA in patients with metastatic breast cancer.
    de Wit R; Hoek FJ; Bakker PJ; Veenhof CH
    Ann Oncol; 1992 Apr; 3(4):314-5. PubMed ID: 1390307
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Estimates of circulating breast cancer-associated antigen CA 15-3 as a monitoring marker in patients with breast cancer].
    Yoshimoto M; Akiyama F; Watanabe S; Kasumi F; Fukami A; Nakajima T; Nishi M; Kajitani T; Takahashi S
    Gan To Kagaku Ryoho; 1987 Jul; 14(7):2310-5. PubMed ID: 3475042
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The value of MCA, CA 15-3, CEA and CA-125 for discrimination between metastatic breast cancer and adenocarcinoma of other primary sites.
    De Wit R; Hoek FJ; Bakker PJ; Veenhof CH
    J Intern Med; 1991 May; 229(5):463-6. PubMed ID: 2040873
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serial measurements of Ca antigen in sera from patients with advanced malignant breast disease.
    Searle F; Chantler SM; Goodall AB; Adam T; Bagshawe KD; Mitchell HD; Boxer GM; Southall PM
    Clin Chim Acta; 1990 Jan; 186(3):351-8. PubMed ID: 2311260
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinoma: influence of histological type, grade of differentiation, and clinical stage of disease.
    Tholander B; Taube A; Lindgren A; Sjöberg O; Stendahl U; Tamsen L
    Gynecol Oncol; 1990 Oct; 39(1):26-33. PubMed ID: 2227570
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gastrointestinal cancer follow-up: the effectiveness of sequential CEA, TPA and Ca 19-9 evaluation in the early diagnosis of recurrences.
    Barillari P; Sammartino P; Cardi M; Ricci M; Gozzo P; Cesareo S; Cerasi A
    Aust N Z J Surg; 1991 Sep; 61(9):675-80. PubMed ID: 1877936
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Diagnostic value of CA 72-4, carcinoembryonic antigen, CA 15-3, and CA 19-9 assay in pleural fluid. A study of 207 patients.
    Villena V; López-Encuentra A; Echave-Sustaeta J; Martín-Escribano P; Ortuño-de-Solo B; Estenoz-Alfaro J
    Cancer; 1996 Aug; 78(4):736-40. PubMed ID: 8756365
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Monitoring breast cancer with CA 549.
    Chan DW; Beveridge RA; Bruzek DJ; Damron DJ; Bray KR; Gaur PK; Ettinger DS; Rock RC
    Clin Chem; 1988 Oct; 34(10):2000-4. PubMed ID: 3168211
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Immunohistochemical determination of antigen 19-9 (CA 19-9) in transitional carcinoma of the bladder].
    Casetta G; Cavallini A; Piana P; Squintone L; Vottero M; Tizzani A
    Minerva Urol Nefrol; 1992; 44(3):169-72. PubMed ID: 1492266
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serum CEA and CA 19-9: potential future diagnostic or screening tests for gallbladder cancer?
    Strom BL; Maislin G; West SL; Atkinson B; Herlyn M; Saul S; Rodriguez-Martinez HA; Rios-Dalenz J; Iliopoulos D; Soloway RD
    Int J Cancer; 1990 May; 45(5):821-4. PubMed ID: 2335386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.